{"denoms":[{"counts":[{"groupId":"BG000","value":"97"}],"units":"Participants"}],"groups":[{"description":"Thalidomide: Start at 3 mg/kg (rounded to nearest 50 mg), increasing dose weekly by 50 mg as tolerated to 24 mg/kg (max 1,000 mg); Celecoxib: \\< 20 kg at 100 mg; 20-50 kg at 200 mg; \\> 50 kg at 400 mg; Fenofibrate: 90 mg/m2 (max 200 mg); Etoposide: 50 mg/m2; Cyclophosphamide: 2.5 mg/kg (max 100 mg); Patients receive oral etoposide once daily on days 1-21 and 43-63 (weeks 1-3 and 7-9) and oral cyclophosphamide once daily on days 22-42 (weeks 4-6). Patients also receive oral thalidomide once daily, oral celecoxib twice daily, and oral fenofibrate once daily in weeks 1-9. Treatment repeats approximately every 9 weeks for at least 3 courses in the absence of disease progression or unacceptable toxicity. Patients receive alternating etoposide and cyclophosphamide pulses (i.e., etoposide-cyclophosphamide-etoposide during courses 1 and 3 and cyclophosphamide-etoposide-cyclophosphamide during course 2).","id":"BG000","title":"5-drug Metronmic Antiangiogenic Regimen"}],"measures":[{"classes":[{"categories":[{"measurements":[{"groupId":"BG000","value":"91"}],"title":"<=18 years"},{"measurements":[{"groupId":"BG000","value":"6"}],"title":"Between 18 and 65 years"},{"measurements":[{"groupId":"BG000","value":"0"}],"title":">=65 years"}]}],"paramType":"COUNT_OF_PARTICIPANTS","title":"Age, Categorical","unitOfMeasure":"Participants"},{"classes":[{"categories":[{"measurements":[{"groupId":"BG000","lowerLimit":"0.52","upperLimit":"21","value":"10"}]}]}],"dispersionType":"FULL_RANGE","paramType":"MEDIAN","title":"Age, Continuous","unitOfMeasure":"years"},{"classes":[{"categories":[{"measurements":[{"groupId":"BG000","value":"47"}],"title":"Female"},{"measurements":[{"groupId":"BG000","value":"50"}],"title":"Male"}]}],"paramType":"COUNT_OF_PARTICIPANTS","title":"Sex: Female, Male","unitOfMeasure":"Participants"},{"classes":[{"categories":[{"measurements":[{"groupId":"BG000","value":"97"}]}],"title":"United States"}],"paramType":"NUMBER","title":"Region of Enrollment","unitOfMeasure":"participants"},{"classes":[{"categories":[{"measurements":[{"groupId":"BG000","value":"21"}]}],"title":"High Grade Glioma"},{"categories":[{"measurements":[{"groupId":"BG000","value":"19"}]}],"title":"Ependymoma"},{"categories":[{"measurements":[{"groupId":"BG000","value":"12"}]}],"title":"Low Grade Glioma"},{"categories":[{"measurements":[{"groupId":"BG000","value":"12"}]}],"title":"Bone Tumors"},{"categories":[{"measurements":[{"groupId":"BG000","value":"8"}]}],"title":"Medulloblastoma/PNET"},{"categories":[{"measurements":[{"groupId":"BG000","value":"3"}]}],"title":"Neuroblastoma"},{"categories":[{"measurements":[{"groupId":"BG000","value":"4"}]}],"title":"Leukemia/Lymphoma"},{"categories":[{"measurements":[{"groupId":"BG000","value":"9"}]}],"title":"Miscellaneous CNS Tumors"},{"categories":[{"measurements":[{"groupId":"BG000","value":"9"}]}],"title":"Miscellaneous non-CNS Tumors"}],"description":"Patients were stratified within 7 disease strata and an 8th 'miscellaneous' stratum.","paramType":"NUMBER","title":"Disease Group","unitOfMeasure":"participants"}],"populationDescription":"The analysis population represents patients who started treatment."}